002630.KS
ORIENT BIO Inc.
KSC · Healthcare · Biotechnology · KR
KRW 913.00
+8.69%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 29.5B | 29.4B | 28.0B | 28.8B | 26.3B |
| Cost of Revenue | 24.4B | 22.2B | 18.4B | 19.0B | 17.3B |
| Gross Profit | 5.2B | 7.2B | 9.6B | 9.8B | 9.0B |
| Operating Expenses | |||||
| R&D Expense | 809.9M | 1.0B | 1.9B | 1.8B | 2.6B |
| SG&A Expense | 4.4B | 3.9B | 3.8B | 3.0B | 2.5B |
| General & Admin Expense | 575.5M | 931.9M | 697.6M | 670.0M | 618.5M |
| Selling & Marketing Expense | 2.0B | 2.9B | 3.1B | 2.3B | 1.9B |
| Other Expenses | 4.4B | 5.4B | 4.5B | (245.4M) | 194.4M |
| Total Operating Expenses | 9.6B | 10.3B | 10.2B | 8.4B | 12.8B |
| Cost and Expenses | 34.0B | 32.5B | 28.7B | 27.4B | 30.1B |
| Operating Income (EBIT) | (4.5B) | (3.1B) | (645.9M) | 1.5B | (3.8B) |
| Non-Operating | |||||
| Interest Income | 1.9B | 1.9B | 2.3B | 1.5B | 818.6M |
| Interest Expense | 156.7M | 220.3M | 56.9M | 252.3M | 432.9M |
| Net Interest Income | 1.7B | 1.7B | 2.2B | 2.4B | 427.4M |
| Other Non-Op Income/Expense | (3.8B) | (10.1B) | 13.5B | (14.0B) | 419.5M |
| Non-Operating Income (excl Interest) | 3.8B | 9.9B | (13.6B) | 13.8B | (852.4M) |
| EBT (Pre-Tax Income) | (8.2B) | (13.2B) | 12.9B | (12.6B) | (3.4B) |
| Income Tax Expense | — | — | — | (167.0M) | 69.1M |
| Bottom Line | |||||
| Net Income | (8.2B) | (13.2B) | 12.9B | (12.4B) | 34.2B |
| Earnings from Cont. Ops | (8.2B) | (13.2B) | 12.9B | (12.4B) | (3.4B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (8.2B) | (13.2B) | 12.9B | (12.4B) | (1.6B) |
| Per Share | |||||
| Basic EPS | (₩69) | (₩111) | ₩109 | (₩105) | (₩13) |
| Diluted EPS | (₩69) | (₩111) | ₩109 | (₩105) | (₩13) |
| Revenue Per Share | ₩249 | ₩248 | ₩236 | ₩243 | ₩222 |
| Shares | |||||
| Basic Shares Outstanding | 118.6M | 118.6M | 118.6M | 118.6M | 118.6M |
| Diluted Shares Outstanding | 118.6M | 118.6M | 118.6M | 118.6M | 118.6M |
| Profitability Metrics | |||||
| EBITDA | (5.7B) | (11.0B) | 15.7B | (9.2B) | 997.2M |
| D&A | 2.1B | 2.0B | 2.7B | 3.1B | 3.9B |
| EBIT | (7.7B) | (13.0B) | 13.0B | (12.3B) | (2.9B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025